TrialBlood2021

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.

Jorge Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.